How Biomarkers Are Changing Heart Disease Treatment

What Are Cardiovascular Biomarkers?

Cardiovascular disease remains the leading global cause of mortality (Roth et al., 2017).¹ Precision cardiology uses molecular markers, imaging, and genetics to refine prevention and acute care, but each marker needs a defined context of use (FDA-NIH, 2016).² Population risk calculators alone often misclassify individuals at the tails of risk, where preventive therapy decisions matter most.

Acute Coronary Syndromes: Troponin Dynamics

Thygesen et al. (2018) center myocardial infarction diagnosis on cardiac troponin release with ischemic symptoms or ECG/imaging correlates.³ High-sensitivity assays lower the detection threshold, so protocols emphasize serial sampling and delta criteria rather than a single emergency-department draw. Trials that use troponin endpoints must prespecify assay generation and cutoff strategy or results will not transport across sites.

Elevated troponin is not MI-specific. Mahmood et al. (2023) review how high-sensitivity cardiac troponin rises in heart failure, myocarditis, pulmonary embolism, and chronic kidney disease, producing false-positive patterns if clinicians treat a single value as binary.⁴ Serial change and clinical context remain essential.

Prognosis in stable cardiovascular disease

Biener et al. (2018) compared high-sensitivity cardiac troponin T (hs-cTnT) alone with the ESC-SCORE in 693 stable low-risk outpatients with and without established cardiovascular disease. hs-cTnT alone outperformed the ESC-SCORE for all-cause mortality prediction (median follow-up 796 days) and was at least as effective for composite cardiovascular endpoints.⁵ That finding does not replace guideline risk scores everywhere, but it illustrates how a widely available analyte can reclassify chronic risk when measured with high-sensitivity methods.

Heart Failure: Natriuretic Peptides and Beyond

Mueller et al. (2019) summarize BNP and NT-proBNP for diagnosis, prognosis, and therapy monitoring in heart failure.⁶ Natriuretic peptides add objective data to congestion assessment; they do not replace echocardiography when structural diagnosis is required.

ST2 and galectin-3 reflect myocardial fibrosis and remodeling pathways partly independent of hemodynamic load. Grande et al. (2017) studied 315 chronic heart failure outpatients with NT-proBNP, ST2, and galectin-3 above guideline cutoffs. A score counting how many markers were elevated (0 to 3) stratified one-year events; multivariate hazard ratio 1.52 (95% CI 1.06 to 2.17, p = 0.023) after adjustment.⁷

Head-to-head comparisons favor ST2 for long-term cardiovascular mortality in some cohorts. Bayes-Genis et al. (2014) followed 876 ambulatory heart failure patients for a median 4.2 years; ST2 remained independently associated with cardiovascular death in multivariate models, while galectin-3 did not add comparable reclassification.⁸ O'Meara et al. (2014) linked the same fibrosis markers to mode of death in HF-ACTION, with stronger associations for pump failure than sudden death after adjustment.⁹ These data support multiparametric panels for prognosis, not automatic therapy changes without trial evidence.

Prevention: Beyond the Pooled Cohort Equations

Khera et al. (2018) showed polygenic risk scores identify individuals with substantially higher coronary disease risk in UK Biobank and other cohorts.¹⁰ PRS are ancestry-sensitive and require calibration before clinical deployment. They augment, rather than replace, guideline-based risk factors.

Lipoprotein(a): Genetics Meets Therapeutics

Tsimikas et al. (2018) summarize NHLBI working-group evidence that lipoprotein(a) is a causal mediator of cardiovascular disease and calcific aortic valve disease, with therapies in clinical development.¹¹ Elevated Lp(a) is common, though assay thresholds vary by laboratory; statins lower LDL-C but tend to increase or not meaningfully reduce Lp(a) (Tsimikas, 2017).¹² Guidelines increasingly recommend one-time measurement to identify patients who may need intensified LDL lowering or enrollment in Lp(a)-lowering trials.

O'Donoghue et al. (2022) reported the OCEAN(a)-DOSE phase 2 trial of olpasiran, an siRNA targeting hepatic apolipoprotein(a) synthesis. The 75-mg dose every 12 weeks produced a placebo-adjusted mean Lp(a) reduction of 97.4% at 36 weeks; higher doses showed similar magnitude.¹³ Nicholls et al. (2024) described sustained Lp(a) lowering months after the last dose in the extension period, with roughly 40 to 50% reduction near one year off treatment at higher doses.¹⁴ Phase 3 outcomes trials (OCEAN(a)-Outcomes, NCT05581303) will test whether Lp(a) lowering reduces coronary events in patients with established ASCVD and elevated Lp(a).

Until outcomes data read out, Lp(a) remains a risk stratification and trial-enrollment biomarker, not proof that every elevated patient needs pharmacologic Lp(a) reduction today.

Emerging Analytes and Multi-Marker Panels

Mahmood et al. (2023) discuss exosomes and other circulating vesicles as candidate cardiovascular biomarkers carrying tissue-specific cargo.⁴ Analytical standardization for vesicle isolation remains a barrier to clinical adoption.

Combining protein, genetic, and imaging markers can improve discrimination but increases overfitting risk without external validation (Ritchie et al., 2015).¹⁵ Any composite score proposed for clinical use should report transportability across sites and assay platforms, not only AUC in a single biobank.

Where Motif Fits Before CV Programs

Cardiovascular biomarker programs span acute care, heart failure, and prevention; literature is scattered across cardiology, lab medicine, and genetics journals. In Motif, scoping typically runs like this:

• Search: Plain-language queries for protein, genetic, or lipid markers with outcome data in your target population.
• Extract: Assay generation, cutoffs, hazard ratios, and treatment interactions from PMIDs, with prognostic and predictive claims labeled separately.
• Cross-reference: Proteins and variants resolve to UniProt, ClinVar, and disease ontologies.
• Export: Cited evidence tables for protocol background, diagnostic memos, and enrichment planning.

Motif does not run clinical tests or prescribe therapy. It gives CV teams a cited literature baseline before assay lock or trial design.

Read our blog on multi-omics biomarker integration to learn more about fusion pitfalls. Read our blog on personalized medicine biomarker analysis to learn more about precision-medicine evidence standards.

Frequently Asked Questions

References

1. Roth, G.A., et al. (2017). Global burden of cardiovascular disease. JACC, 70(1), 1-25. PMID: 28842454
2. FDA-NIH Biomarker Working Group. (2016). BEST Resource. PMID: 27010052
3. Thygesen, K., et al. (2018). Fourth universal definition of MI. Circulation, 138(20), e618-e651. PMID: 30571511
4. Mahmood, S.S., et al. (2023). New biomarkers for cardiovascular disease. Arch Pathol Lab Med, 147(11), 1262-1274. PMID: 37846107
5. Biener, M., et al. (2018). hs-cTnT vs ESC-SCORE in stable CVD. Open Heart, 5(1), e000710. PMID: 29713483
6. Mueller, C., et al. (2019). Natriuretic peptides in HF. Eur Heart J, 40(1), 25-33. PMID: 31504439
7. Grande, D., et al. (2017). Multiparametric NT-proBNP, ST2, and galectin-3 approach in CHF. J Cardiovasc Dev Dis, 4(3), 9. PMID: 29367540
8. Bayes-Genis, A., et al. (2014). ST2 vs galectin-3 in HF risk stratification. J Am Coll Cardiol, 63(2), 158-166. PMID: 24076531
9. O'Meara, E., et al. (2014). Biomarkers of stress and fibrosis and mode of death in HF-ACTION. Circ Heart Fail, 7(6), 1062-1069. PMID: 24952693
10. Khera, A.V., et al. (2018). Polygenic risk scores for coronary disease. Nat Genet, 50(9), 1219-1224. PMID: 29930141
11. Tsimikas, S., et al. (2018). NHLBI working group on Lp(a)-mediated CVD risk. J Am Coll Cardiol, 71(2), 177-192. PMID: 29325642
12. Tsimikas, S. (2017). Lipoprotein(a): diagnosis, prognosis, and therapies. J Am Coll Cardiol, 69(6), 692-711. PMID: 28183512
13. O'Donoghue, M.L., et al. (2022). Small interfering RNA to reduce Lp(a) in CVD. NEJM, 387(20), 1855-1864. PMID: 36342163
14. Nicholls, S.J., et al. (2024). Off-treatment effects of olpasiran on Lp(a). JACC, 84(9), 893-903. PMID: 39168564
15. Ritchie, M.D., et al. (2015). Methods of integrating data to uncover genotype-phenotype interactions. Nat Rev Genet, 16(2), 85-97. PMID: 25582081